News

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital project in the 95-year-old university’s history — a new biological sciences building.

The planned five-story, 162,586 square-foot building will be located on ‘s campus in , near the university’s Oceanography and Mills Godwin Life Sciences buildings.

ODU spokesperson Jonah Ross Grinkewitz said the $184 million project is funded by a state bond issue and will house classrooms, teaching laboratories, a 120-seat lecture hall and other student support spaces. State and campus leaders, and community members gathered Monday to commemorate the .

“Today would not be possible without significant support from the Commonwealth of Virginia,” said President Brian O. Hemphill in a Monday statement. “With the leadership and action of Gov. Youngkin and the General Assembly, a $184 million investment has been made in Old Dominion University, specifically our students, representing the largest in the history of our institution in terms of both scope and size.”

The building is meant to support faculty and student research in biomedical and ecological areas. As part of the project, the Arthur and Phyllis Kaplan Orchid Conservatory will be relocated within the biological sciences building with an added water feature and a two-story tropical display house. The exterior design incorporates an existing pond and features a terraced seating area.

A team that includes VMDO Architects, Ballinger and O’Shea Wilson Site Works designed the building. Newport News-based will serve as the project’s general contractor.

The building is expected to be ready for use in spring 2028.

Virginia Secretary of Education Aimee Guidera said the building embodies the ODU’s mission of being a “forward-focused, innovative and entrepreneurial research university.

“The pioneering biological research conducted at this state-of-the-art research and development hub will prepare students to succeed in their lives and careers beyond graduation,” Guidera added in a statement.

Read more here.

 

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and